Laboratory Corp American Holdings is a leading global life sciences company that offers comprehensive laboratory services, including diagnostic testing and drug development support
They operate advanced clinical laboratories that conduct a wide array of tests, specializing in areas such as genetics, infectious diseases, and routine screenings. The company also provides end-to-end solutions for the pharmaceutical and biotechnology industries, assisting in the development of new therapies and drugs through clinical trial testing and regulatory support. By leveraging cutting-edge technology and a vast network of resources, Laboratory Corp aims to improve healthcare outcomes and enhance patient care through accurate and timely laboratory results.
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,
and over the past six months, the industry has pulled back by 9.4%. This performance was disheartening since the S&P 500 held its ground.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Quest (NYSE:DGX) and the best and worst performers in the testing & diagnostics services industry.
Over the past six months, Labcorp has been a great trade, beating the S&P 500 by 6.9%. Its stock price has climbed to $255.01, representing a healthy 13.9% increase. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
The research firm noted that post-pandemic utilization rates have remained high, and Labcorp is positioned to capitalize on this trend through its core diagnostics business.
Healthcare diagnostics company Labcorp Holdings (NYSE:LH) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 9.8% year on year to $3.33 billion. The company’s full-year revenue guidance of $13.97 billion at the midpoint came in 1.4% above analysts’ estimates. Its non-GAAP profit of $3.45 per share was 1.7% above analysts’ consensus estimates.
Labcorp's Q4 EPS of $3.45 topped estimates, with sales rising 9.8% to $3.33 billion. 2025 guidance points to continued growth in diagnostics and biopharma.
Labcorp considers boosting its mpox testing capacity as the WHO declares a global health emergency. Companies like Roche and Quest Diagnostics are also monitoring demand and expanding testing services.
Top 10 stocks with highest gains last week, including Exact Sciences, Alnylam Pharmaceuticals, Resmed, Coca-Cola Consolidated, DexCom, Sprouts Farmers Market, UL Solutions, Labcorp Holdings, C.H. Robinson Worldwide, and DoorDash.
LabCorp reported Q2 2024 adjusted EPS of $3.94, surpassing expectations of $3.78. Sales increased by 6.2% to $3.22 billion, driven by organic revenue growth and acquisitions. LabCorp revised its 2024 EPS outlook to $14.30-$14.90 and raised revenue growth projections to 6.4%-7.5%.
